Please login to the form below

Not currently logged in
Email:
Password:

CMV

This page shows the latest CMV news and features for those working in and with pharma, biotech and healthcare.

EC grants MSD’s Prevymis orphan product designation

EC grants MSD’s Prevymis orphan product designation

EC grants MSD’ s Prevymis orphan product designation. The product will gain some market exclusivity benefits in CMV infection. ... The status for Prevymis ’ (letermovir) covers the prophylaxis of cytomegalovirus (CMV) reactivation and disease in

Latest news

  • Shire’s Maribavir wins US breakthrough therapy designation Shire’s Maribavir wins US breakthrough therapy designation

    The US Food and Drug Administration (FDA) has granted a breakthrough therapy designation to Shire’s investigational treatment for cytomegalovirus (CMV) infection in transplant patients. ... According to Shire, the investigational treatment operates by

  • CHMP backs MSD’s CMV infection treatment CHMP backs MSD’s CMV infection treatment

    CHMP backs MSD’ s CMV infection treatment. Prevymis is set to be available as an injectable and tablets. ... In 2014, there were 1, 346 non-paediatric allogeneic HSCT procedure performed in the UK and up to 50% of CMV seropositive recipients of

  • Merck says drug for CMV in transplant patients hits targets Merck says drug for CMV in transplant patients hits targets

    CMV is a herpes virus, infecting 50-90% of the adult population, with a majority remaining without symptoms. ... The company's good news comes after another CMV drug developer - Chimerix - reported that its brincidofovir CMV candidate failed a pair of

  • Chimerix hit as lead drug brincidofovir flunks trial Chimerix hit as lead drug brincidofovir flunks trial

    The phase III trial of the drug - a treatment for cytomegalovirus (CMV) infections in people undergoing stem cell transplants to repopulate bone marrow - was unable to show a significant reduction in ... Both GVHD and use of corticosteroids are risk

  • Vical's genital herpes vaccine flunks trial Vical's genital herpes vaccine flunks trial

    Samant said the company would now concentrate on the four other vaccine candidates in its pipeline, the most advanced of which is cytomegalovirus (CMV) vaccine ASP0113, developed in partnership with Astellas

More from news
Approximately 4 fully matching, plus 11 partially matching documents found.

Latest Intelligence

  • Pharma deals during January 2013 Pharma deals during January 2013

    VPM. Cevec. Licence. CMV dense body technology in vaccines. Biological E .

  • Pharma deals during October 2012 Pharma deals during October 2012

    In addition to letermovir, this deal gives Merck rights to an additional back-up CMV drug candidate, and other phase I CMV assets that have a different mechanism of action. ... 587. AiCuris / Merck &Co. Licence. Letermovir (phase IIb) and antiviral

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
wethepeople

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
What everyone forgets about good organisational change in pharma
Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....
Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies
Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST...

Infographics